Trials / Completed
CompletedNCT03926130
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,158 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 15 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirikizumab | Administered IV |
| DRUG | Mirikizumab | Administered SC |
| DRUG | Ustekinumab | Administered IV |
| DRUG | Ustekinumab | Administered SC |
| DRUG | Placebo | Administered IV |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2019-07-23
- Primary completion
- 2023-08-23
- Completion
- 2023-10-02
- First posted
- 2019-04-24
- Last updated
- 2024-12-27
- Results posted
- 2024-12-27
Locations
580 sites across 34 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Croatia, Czechia, Denmark, France, Germany, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Korea, Spain, Switzerland, Turkey (Türkiye), Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03926130. Inclusion in this directory is not an endorsement.